360° UPSC Mains Analysis

India

The monsoon pattern in India, characterized by southwest and northeast monsoons, creates seasonal waterlogging conducive to Aedes mosquito breeding. Rising temperatures and changing precipitation patterns due to climate change are driving the vector into higher elevations and previously unaffected rural regions.

The analysis spans South Asia (India), Southeast Asia (Philippines), and East Asia (Japan). India's vast peninsular geography and extensive river basins create diverse ecological niches that facilitate vector-borne disease transmission.

The geographic spread of dengue heavily impacts human resources and economic productivity, particularly affecting dense urban slums and the mobile migrant workforce across major economic corridors in India.

Under the Seventh Schedule, 'Public health and sanitation' is a State subject (List II, Entry 6), making the physical rollout of vaccines and vector control primarily the responsibility of state governments. However, 'Drugs and poisons' (List III, Entry 19) and 'Prevention of the extension from one State to another of infectious or contagious diseases' (List III, Entry 29) fall under the Concurrent List. This shared jurisdiction enables the Central Government to centrally regulate vaccine approvals and pricing while collaborating with states for localized distribution.

Initially, importing Qdenga from Takeda GmbH (Germany) will increase pharmaceutical imports, temporarily widening the trade deficit. However, the manufacturing partnership with Biological E. Limited in Hyderabad will eventually transition India into a local production hub, potentially enabling vaccine exports to other dengue-endemic countries in Asia and Latin America.

The introduction of Qdenga can mitigate India's massive economic burden from dengue, which was estimated at $6.7 billion in 2017. By reducing hospitalizations and severe cases, it will lower public healthcare expenditure, potentially easing the fiscal deficit under the National Health Mission. However, importing the vaccine from Takeda GmbH (Germany) before local manufacturing by Biological E. begins in 2027 may temporarily impact the current account and forex reserves.

The tertiary sector (healthcare services) will see a reduction in seasonal hospital bed occupancy and emergency strain during monsoon surges. The secondary sector (pharmaceutical manufacturing) will benefit through the technology transfer and local production partnership between Takeda and Hyderabad-based Biological E. Limited.

Dengue episodes cause an average wage loss of 8 days per patient, severely impacting the informal and migrant workforce. Reducing infection rates will protect household incomes by lowering high out-of-pocket expenditures (OOPE), which average ₹6,860 per episode, preventing vulnerable families from falling into medical debt.

The regulatory framework for drug and vaccine approvals in India traces back to the colonial-era Drugs and Cosmetics Act, 1940, enacted to regulate the import, manufacture, and distribution of drugs. Historically, India's public health strategy during the colonial and early post-independence eras focused primarily on vector control (such as DDT spraying for malaria) rather than immunization for vector-borne diseases. Under the Constitution of India, 'Public health and sanitation' is a State subject (Seventh Schedule, List II, Entry 6), while 'Drugs and poisons' falls under the Concurrent List (List III, Entry 19), shaping the federal dynamics of vaccine rollouts.

Post-independence, India launched the National Malaria Control Programme in 1953, which later evolved into the National Vector Borne Disease Control Programme (NVBDCP) in 2003-04 to integrate the control of six vector-borne diseases, including dengue. Vaccine policy shifted from basic immunization under the Expanded Programme on Immunization (EPI) in 1978 to incorporating advanced vaccines under the National Vaccine Policy, 2011. The regulatory mechanism was further strengthened with the establishment of the Central Drugs Standard Control Organisation (CDSCO) and the introduction of the New Drugs and Clinical Trial Rules, 2019, to streamline approvals while ensuring safety.

The introduction of the Japanese Encephalitis (JE) vaccine in 2006 following a massive outbreak in 2005 serves as a direct parallel, where India transitioned from vector control to targeted immunization in high-burden districts. Similarly, the phased rollout and safety controversies surrounding the Pentavalent vaccine's introduction in 2011 highlight the challenges of balancing public health urgency with rigorous post-marketing surveillance and public trust.

The early focus on indigenous vaccine development and self-reliance in public health was deeply influenced by the Swadeshi movement, which championed local scientific institutions like the Haffkine Institute (established in 1899) to counter colonial dependence during epidemics.

The expansion of Aedes mosquito vectors into semi-urban and rural districts alters local ecological dynamics and food webs. Uncontrolled vector control measures, such as intensive chemical fogging, can lead to bioaccumulation of pesticides and non-target toxicity in local biodiversity, particularly affecting beneficial insects and aquatic ecosystems.

The Qdenga vaccine (TAK-003) is a live-attenuated tetravalent vaccine designed using recombinant DNA technology where the pre-membrane and envelope proteins of DENV-1, DENV-3, and DENV-4 are engineered into a weakened DENV-2 backbone. This design aims to trigger a balanced immune response against all four antigenically distinct dengue serotypes to prevent antibody-dependent enhancement (ADE).

Climate change, characterized by rising temperatures and erratic rainfall patterns, accelerates the breeding cycles and expands the geographical range of Aedes mosquitoes into previously cooler, high-altitude regions. This directly undermines India's adaptation goals under the National Action Plan on Climate Change (NAPCC), specifically the National Programme on Climate Change and Human Health (NPCCHH) launched by the Ministry of Health and Family Welfare.

Directly addresses SDG 3 (Good Health and Well-being) by targeting the reduction of vector-borne diseases, and SDG 6 (Clean Water and Sanitation) as poor drainage and inadequate waste management in urban slums create breeding grounds for vectors. It also aligns with SDG 13 (Climate Action) by highlighting the need for climate-resilient health systems.

Dengue infections lead to catastrophic out-of-pocket health expenditure, pushing vulnerable families into poverty and disrupting the livelihoods of daily wage earners. For migrant workers, the lack of a portable healthcare tracking system for the two-dose vaccine regimen threatens their right to complete and safe immunization.

The issue directly intersects with Article 21 of the Constitution of India, which guarantees the Right to Life, interpreted by the Supreme Court in Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996) to include the Right to Health. It also aligns with Directive Principles of State Policy (DPSP) under Article 47, which mandates the State to regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties.

As a District Magistrate, I would face the ethical conflict of Equity vs. Market-driven Access, where the high cost of the vaccine might exclude the most vulnerable slum dwellers who need it most. There is also a conflict of Public Safety vs. Autonomy in managing vaccine hesitancy and ensuring compliance for the two-dose regimen among highly mobile migrant populations, alongside the ethical responsibility of administering a vaccine with varying efficacy against emerging serotypes like DENV-3.

Children are highly vulnerable due to potential 'negative efficacy' against DENV-3 hospitalization in seronegative individuals, as highlighted in the TIDES trial. Economically Weaker Sections (EWS) and slum dwellers face disproportionate risk due to poor drainage infrastructure and the high cost of the vaccine. Highly mobile migrant workers are also vulnerable to incomplete immunization schedules due to the difficulty of tracking them for the required two-dose regimen.